Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer

Changing the standard treatment for lymphoma with bendamustine

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Continuing bevacizumab with second-line chemotherapy for colorectal cancer

Combined chemo-radiation extends survival in patients with anaplastic oligodendroglial tumours

Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer

Lower-income Patients are less likely to participate in clinical trials

Bendamustine regimen more effective for lymphoma than standard CHOP

Early results from new PD-1 targeted immune therapy

New study asks patients preference on kidney cancer treatment

Relapse and survival of adolescent and young adult leukaemia patients

Adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer improves progression-free survival